BioCentury | Dec 21, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

...Capital Partners and existing investors New Enterprise Associates, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management...
BioCentury | Dec 19, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

...Capital Partners and existing investors New Enterprise Associates, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management. Sandi...
BioCentury | Mar 17, 2017
Financial News

Aerpio Pharmaceuticals completes venture financing

...investors Montrose Capital Partners and Ally Bridge Group and existing investors Novartis Venture Fund, OrbiMed, Satter Investment Management...
BioCentury | Mar 16, 2017
Financial News

Aerpio raises $40M ahead of planned OTC listing

...Capital Partners and Ally Bridge Group participated, as did existing investors Novartis Venture Fund, OrbiMed, Satter Investment Management...
BioCentury | Jun 27, 2016
Financial News

Annexon completes venture financing

...financing Raised: $44 million Investors: New Enterprise Associates; Correlation Ventures; Novartis Venture Fund; Clarus ; Satter Investment Management WIR...
BioCentury | Jun 24, 2016
Financial News

Annexon raises $44M in B round

...investor Correlation Ventures also participated, as did existing investors including Novartis Venture Fund, Clarus and Satter Investment Management...
BioCentury | May 18, 2015
Finance

Planting Fidelity's seeds

...December 2014, Annexon raised $34 million in a series A-1 round with Novartis Venture Fund, Satter Investment Management...
BioCentury | Dec 22, 2014
Financial News

Annexon completes venture financing

...Neurology, Autoimmune Date completed: 2014-12-15 Type: Venture financing Raised: $34 million Investors: Novartis Venture Funds; Satter Investment Management...
BioCentury | Dec 22, 2014
Company News

Annexon board of directors update

...Clarus Ventures; Campbell Murray, managing director at Novartis Venture Funds; and Muneer Satter, principal at Satter Investment Management WIR...
BioCentury | Dec 22, 2014
Finance

Annexon connections

...round, led by Novartis Venture Fund, with participation by private investment firm and family office Satter Investment Management...
Items per page:
1 - 10 of 18
BioCentury | Dec 21, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

...Capital Partners and existing investors New Enterprise Associates, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management...
BioCentury | Dec 19, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

...Capital Partners and existing investors New Enterprise Associates, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management. Sandi...
BioCentury | Mar 17, 2017
Financial News

Aerpio Pharmaceuticals completes venture financing

...investors Montrose Capital Partners and Ally Bridge Group and existing investors Novartis Venture Fund, OrbiMed, Satter Investment Management...
BioCentury | Mar 16, 2017
Financial News

Aerpio raises $40M ahead of planned OTC listing

...Capital Partners and Ally Bridge Group participated, as did existing investors Novartis Venture Fund, OrbiMed, Satter Investment Management...
BioCentury | Jun 27, 2016
Financial News

Annexon completes venture financing

...financing Raised: $44 million Investors: New Enterprise Associates; Correlation Ventures; Novartis Venture Fund; Clarus ; Satter Investment Management WIR...
BioCentury | Jun 24, 2016
Financial News

Annexon raises $44M in B round

...investor Correlation Ventures also participated, as did existing investors including Novartis Venture Fund, Clarus and Satter Investment Management...
BioCentury | May 18, 2015
Finance

Planting Fidelity's seeds

...December 2014, Annexon raised $34 million in a series A-1 round with Novartis Venture Fund, Satter Investment Management...
BioCentury | Dec 22, 2014
Financial News

Annexon completes venture financing

...Neurology, Autoimmune Date completed: 2014-12-15 Type: Venture financing Raised: $34 million Investors: Novartis Venture Funds; Satter Investment Management...
BioCentury | Dec 22, 2014
Company News

Annexon board of directors update

...Clarus Ventures; Campbell Murray, managing director at Novartis Venture Funds; and Muneer Satter, principal at Satter Investment Management WIR...
BioCentury | Dec 22, 2014
Finance

Annexon connections

...round, led by Novartis Venture Fund, with participation by private investment firm and family office Satter Investment Management...
Items per page:
1 - 10 of 18